# A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

> **NCT03343652** · PHASE1,PHASE2 · COMPLETED · sponsor: **St. Petersburg State Pavlov Medical University** · enrollment: 30 (actual)

## Conditions studied

- Hodgkin's Lymphoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Bendamustine Hydrochloride

## Key facts

- **NCT ID:** NCT03343652
- **Lead sponsor:** St. Petersburg State Pavlov Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-27
- **Primary completion:** 2019-03-27
- **Final completion:** 2020-03-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03343652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03343652, "A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT03343652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*